Gut, 1987, 28, 1454–1459

Relationship between duodenal bile acids and colorectal neoplasia

R J Moorehead, G R Campbell, J D Donaldson, and S T D McKelvey

From the Department of Surgery, The Queen’s University of Belfast, Belfast, Northern Ireland

SUMMARY To investigate a possible relationship between bile acids and colorectal neoplasia duodenal bile acids were analysed in 50 patients with colorectal adenomas and 14 with carcinoma. Using gas liquid and high performance liquid chromatography a small, but significant increase in the proportion of chenodeoxycholic acid was found in the bile of adenoma patients compared with controls (mean % ± SD 31.0 ± 10.8, 26.4 ± 8.3, p=0.01). The difference in the proportions of chenodeoxycholic acid correlated with increasing malignant potential of the adenomas as determined by increasing size, histological type, degree of dysplasia and number present. In carcinoma patients an increase in the proportion of chenodeoxycholic acid was also observed compared with controls (mean % ± SD, 47.2 ± 9.6, 28.0 ± 4.5, p<0.01). The proportions of other bile acids in those with adenoma or carcinoma were normal.

Bile acids are believed to play a role in the aetiology of colorectal cancer, and this theory is supported by reports of increased concentrations of bile acids in the faeces of those from countries with a high incidence of the disease. It is further supported by reports of increased concentrations of faecal bile acids in those with colorectal adenomas or carcinomas when compared with healthy individuals from the same high risk community. Such studies together with a considerable amount of experimental evidence suggest a definite relationship between bile acids and the pathogenesis of large bowel cancer. Others finding no correlation between faecal bile acids and the presence or risk of colorectal cancer have raised some doubts over the proposed role of bile acids. The measurement of bile acids in faeces is a complex process and it is possible that methodological problems could account for some of these varied findings. Two recent studies, although small, have been unable to confirm a relationship between increased concentrations of faecal bile acids and the presence of colorectal adenomas or carcinomas. Both are critical of the methods used in earlier investigations and suggest that methodological problems may account for the different results. Others have stressed the need for standardising such methods before any valid comparisons can be made.

Alternative means of determining the role of bile acids in the development of colonic cancer have been sought. In a study of colonic absorption of bile acids it was observed that those with adenomas had increased levels of secondary bile acids in duodenal bile. Although only a small number of subjects were studied, the results suggest that duodenal bile analysis may give useful information on the proposed link between bile acids and colorectal adenomas or carcinomas.

The aim of the present study was to determine whether subjects with colorectal adenomas or carcinomas have abnormal duodenal bile acid profiles when compared with healthy controls.

Methods

Patients

The adenoma group comprised 50 patients (28 men, 22 women). The mean ± SD age of the group was 63.6 ± 11.4 years. After resection at colonoscopy the adenomas were classified as either tubular, tubulovillous or villous in type and the degree of dysplasia graded from none to mild, moderate, severe (carcinoma in situ) or malignant. The patients returned at a
later date for duodenal bile sampling. None had undergone previous gastric or intestinal surgery. Three had previous cholecystectomy. In six the gall bladder was known to be normal and in 41 cases the condition of the gall bladder was unknown.

The control group comprised 50 healthy people being investigated for peptic ulceration and hiatus hernia. Their mean ± SD age was 53-4 ± 16-0 years. In 32 cases the gall bladder was known to be normal and functioning as determined by ultrasound or cholecystography, and in 18 cases the condition of the gall bladder was unknown.

Fourteen patients (seven men, seven women) with previously resected carcinomas were studied. The mean ± SD age of the group was 69-1 ± 12-5 years. Eleven had rectal tumours, three had sigmoid tumours. The mean ± SD age difference between surgical resection and bile sampling was 45-2 ± 36-1 months. Ten of the group were known to have normal gall bladders and in four cases the condition of the gall bladders, although present, was not known. All had normal liver function tests. One patient had had a previous partial gastrectomy for peptic ulceration. Age and sex matched controls were drawn from the same group from which the adenoma controls were obtained.

All patients and controls were well, on a normal diet and with a normal bowel habit. None were on drug therapy likely to affect bile acid metabolism or absorption.

After an overnight fast an intravenous injection of Pancreozym (Boots) was given. An Olympus Q-10 endoscope was passed until its tip reached the ampulla of Vater. Residual juice was aspirated and discarded. When a good flow of bile was visualised it was collected and stored at −60°C until later analysis using the techniques of gas liquid and high performance chromatography.

Gas liquid chromatography (GLC) analysis was carried out on the methylated, trimethylsilyl derivatives of the acids after enzymatic deconjugation. A Pye series 104 chromatograph, model 64, equipped with a hydrogen flame detector, temperature programming unit and injection point heaters, with a Pye unican PU4810 computing integrator for recording traces was used. Columns were packed with 1% Hi Eff 8BP gas chrom Q 100/120 mesh (Field Analytical Company Ltd). The carrier gas (nitrogen) and detector gas (hydrogen) flow rates were 650 ml/min. The oven temperature was 220°C.

The technique for high performance liquid chromatography (HPLC) analysis was based on methods described by Alme and Nystrom and Goto et al. A Waters model M45 pump, Waters UBondpak C18 column, Reodyne 1257 injection valve, UVicord S Detector (LKB) and a Hewlett Packard 3390A integrator were used.

Results

Gas liquid chromatography analysis detected seven bile acids in duodenal bile: cholic acid (CA), an unidentified acid (XA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), lithocholic acid (LCA), a second unidentified acid (YA) and ursodeoxycholic acid (UDCA) (Table 1).

There was a significant increase in the proportion of chenodeoxycholic acid present in the bile of adenoma patients compared with controls, 31-0%: 26-4%, p=0-01. The proportions of the other bile acids in the adenoma group did not differ from control values. There was a trend, however, for a decrease in the proportion of cholic acid present in the bile of the adenoma group, 46-5%: 50-9% (p=0-07).

When the adenomas were single, 2 cm or less in diameter, tubular in type or having either no or only mild dysplastic changes, the bile acid profiles were not different from those of the controls. When the adenomas were multiple, larger than 2 cm, tubulovillous or villous in type, or having moderate to severe dysplastic changes, significant differences between the bile acid profiles of these subjects and the controls were observed (Table 2). In all of these subgroups the proportion of chenodeoxycholic acid present was increased and when moderate to severe degrees of dysplasia were present, a decrease in the proportion of cholic acid was present, 44-1%: 51-1%, p=0-02. The proportions of the other bile acids present in these subgroups was normal.

Carcinoma patients also had an increase in the proportion of chenodeoxycholic acid, 42-2%: 28-0%, p<0-01 (Table 3). There was no difference between the proportions of the other bile acids present.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Mean percentages ± SD of bile acids in adenoma group and controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CA</td>
</tr>
<tr>
<td>n = 50</td>
<td></td>
</tr>
<tr>
<td>Adenoma group</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td></td>
<td>11-9</td>
</tr>
<tr>
<td>Control group</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td></td>
<td>13-0</td>
</tr>
</tbody>
</table>
though again there was a trend for lower levels of cholic acid in the carcinoma group.

High performance liquid chromatography identified eight bile acids in 38 of the adenoma patients. These were the glycine and taurine conjugates of cholic (G+TCA), deoxycholic (G+TDCA), chenodeoxycholic (G+TCDCA) and lithocholic acids (G+TLCA). Ursodeoxycholic acid was not identified using HPLC. Up to five unidentified peaks were observed in the samples from adenoma patients and controls.

The tauro and glyco fractions of each bile acid in the adenoma group were compared with the controls (Tables 4 and 5). The increase in the proportions of chenodeoxycholic acid in the adenoma group was confirmed, 37.7%-31.9%, p=0.04, and this was mainly in the glycine fraction (26.3%-21.9%, p=0.05). As with GLC analysis there was no difference between the proportions of the other bile acids present.

**Discussion**

We have shown that patients with colorectal adenomas have abnormal duodenal bile acid profiles when compared with matched controls. The principal difference between the two groups was a small but significant increase in the proportion of chenodeoxycholic acid in the bile of those with adenomas which correlated with increasing malignant potential as determined by increasing size, number, histological type and the degree of dysplasia present. This was matched by a decrease in the proportion of cholic acid present in the adenoma group although this did not reach statistical significance. Similar differences were found in the bile of those with previous carcinomas and had a larger number of such patients been studied the reciprocal fall in the proportion of

### Table 2  Proportions of chenodeoxycholic acid in adenoma subgroups compared with controls

<table>
<thead>
<tr>
<th>Malignant potential of adenomas</th>
<th>Group (n)</th>
<th>Mean % ± SD chenodeoxycholic acid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Adenoma</td>
</tr>
<tr>
<td>Size less than or equal to 2cm</td>
<td>31</td>
<td>31-0 ± 11-3</td>
</tr>
<tr>
<td>Size &gt;2cm</td>
<td>19</td>
<td>31-2 ± 10-0</td>
</tr>
<tr>
<td>Tubular</td>
<td>13</td>
<td>27-1 ± 10-4</td>
</tr>
<tr>
<td>Intermediate or villous</td>
<td>35</td>
<td>32-4 ± 10-6</td>
</tr>
<tr>
<td>None or mild dysplasia</td>
<td>22</td>
<td>27-5 ± 10-0</td>
</tr>
<tr>
<td>Moderate or severe dysplasia</td>
<td>28</td>
<td>33-8 ± 10-6</td>
</tr>
<tr>
<td>Number = 1</td>
<td>29</td>
<td>29-1 ± 11-3</td>
</tr>
<tr>
<td>Number equal to or greater than 2</td>
<td>21</td>
<td>33-8 ± 9-3</td>
</tr>
</tbody>
</table>

### Table 3  Mean percentages ± SD of bile acids present in carcinoma patients and controls

<table>
<thead>
<tr>
<th>n = 14</th>
<th>CA</th>
<th>XA</th>
<th>DCA</th>
<th>CDCA</th>
<th>LCA</th>
<th>YA</th>
<th>UDCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer group</td>
<td>Mean % ± SD</td>
<td>36-5</td>
<td>4-9</td>
<td>16-0</td>
<td>42-2</td>
<td>0-0</td>
<td>0-0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9-9</td>
<td>2-8</td>
<td>8-7</td>
<td>9-6</td>
<td>0-0</td>
<td>0-0</td>
</tr>
<tr>
<td>Control group</td>
<td>Mean % ± SD</td>
<td>47-5</td>
<td>2-7</td>
<td>21-6</td>
<td>28-0</td>
<td>0-1</td>
<td>0-0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11-8</td>
<td>3-3</td>
<td>10-9</td>
<td>4-5</td>
<td>0-2</td>
<td>0-0</td>
</tr>
</tbody>
</table>

### Table 4  Mean percentages ± SD of combined tauro and glycoconjugates in adenoma and control groups

<table>
<thead>
<tr>
<th>n = 50</th>
<th>T+GCA</th>
<th>T+GCDCA</th>
<th>T+GDCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenoma group</td>
<td>Mean %</td>
<td>41-8</td>
<td>37-7</td>
</tr>
<tr>
<td></td>
<td>± SD</td>
<td>11-3</td>
<td>8-9</td>
</tr>
<tr>
<td>Control group</td>
<td>Mean %</td>
<td>43-5</td>
<td>31-9</td>
</tr>
<tr>
<td></td>
<td>± SD</td>
<td>11-5</td>
<td>9-7</td>
</tr>
</tbody>
</table>

### Table 5  Mean percentages ± SD of the conjugates of each bile acid present in the adenoma group and controls

<table>
<thead>
<tr>
<th>n = 50</th>
<th>TCA</th>
<th>TCDCA</th>
<th>TDCA</th>
<th>GCA</th>
<th>GCDCA</th>
<th>GDCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenoma group</td>
<td>Mean % ± SD</td>
<td>12-8</td>
<td>11-4</td>
<td>2-6</td>
<td>28-9</td>
<td>26-3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6-2</td>
<td>7-9</td>
<td>5-8</td>
<td>9-8</td>
<td>9-9</td>
</tr>
<tr>
<td>Control group</td>
<td>Mean % ± SD</td>
<td>12-0</td>
<td>10-0</td>
<td>3-1</td>
<td>31-5</td>
<td>21-9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6-8</td>
<td>5-9</td>
<td>2-5</td>
<td>9-1</td>
<td>8-0</td>
</tr>
</tbody>
</table>
cholic acid may have reached statistical significance.

These results support those recently reported by Owen et al. They studied the major bacterial metabolites of chenodeoxycholic acid and cholic acid. They observed an increased ratio of lithocholic to deoxycholic acid in the faeces of some adenoma and cancer patients compared with controls and this is in keeping with the increased concentrations of chenodeoxycholic acid seen in the bile of our tumour bearing patients.

The results of this study appear to contradict those of Van der Werf et al. They were the first to report abnormalities in duodenal bile acids of those with adenomas. They reported an increase in the proportion of secondary bile acids, principally deoxycholic acid, at the expense of a decrease in cholic acid. While the fall in the level of cholic acid would be in agreement with our findings, we could not confirm the finding of increased concentrations of deoxycholic acid in these patients. In their original study group of 11 adenoma patients, three had undergone previous cholecystectomy. Such a group are known to have increased concentrations of secondary bile acids and this may have influenced their results.

The differences in this study in the proportions of chenodeoxycholic acid between adenoma patients and controls, although significant, were small and raises the question whether the methods of bile acid analysis were sufficiently accurate and reliable to show such small differences. Studies on reproducibility showed recovery rates of bile acids that were high and consistent. Using high performance liquid chromatography (HPLC) increased proportions of chenodeoxycholic acid were confirmed in adenoma patients. This gives confidence in the accuracy of the laboratory methods used.

The use of HPLC permitted the determination of glycine and taurine conjugates of the bile acids. It revealed an increase in the glycine fraction and not the taurine conjugate. Glycine conjugates normally exceed those of taurine but the selective increase in the type of conjugation observed in this study remains unexplained.

Does removal of the adenoma or carcinoma affect the bile acid profiles? In the majority of cases the duodenal bile samples were obtained some time after polypectomy or resection of the carcinomas. The differences observed have persisted despite removal of the tumours. The correlation with increasing malignant potential suggests a causal relationship and may also have a bearing on the development of metachronous tumours.

Gall bladder function has a major influence on bile acid metabolism. Where the state of the gall bladder is unknown there is the possibility of cholelithiasis or non-function. With the majority of the controls having normal gall bladders and the majority of the adenoma patients having undetermined gall bladder status and function, a possible, although unavoidable, source of error may have existed.

Variations in bile acid metabolism with age are known to occur and include less effective absorption of cholic acid in the elderly. To allow for these differences we tried to match for age as closely as possible but on average our controls were approximately 10 years younger than the adenoma patients. An increase in the proportion of secondary bile acids in duodenal bile was not observed, suggesting that failure to achieve good age matching did not affect the outcome of the study.

Some unknown peaks were identified on the chromatographs obtained using both GLC and HPLC, which may have been unknown bile acids or simply artefacts produced during the process of analysis. Strong alkaline hydrolysis of sulphate esters, as commonly occurs during bile acid analysis, can result in a number of degradation products producing abnormal peaks. While this might explain these findings, it seems unlikely as the hydrolysis used in our GLC analysis is a weak one. These unknown peaks may therefore represent bile acids and the unknown peaks obtained with HPLC may represent their glycine and taurine conjugates. As they appeared equally in patients and controls they are probably irrelevant in the context of colorectal neoplasia.

Until the possible role of chenodeoxycholic acid and its metabolites in the pathogenesis of colorectal adenomas and carcinomas is defined, it is reasonable to suggest caution in the use of such a bile acid in the medical treatment of cholelithiasis. This cautionary note is shared by Sachatello et al. and Williamson and Rainey.

The results of this study pose more questions than they answer. The possible abnormalities in bile acid metabolism of those with adenomas and carcinomas suggests a need for further studies to investigate terminal ileal function, colonic absorption of bile acids and bile acid pool sizes in these individuals.

In conclusion, by showing differences between the bile acid profiles of patients with colorectal adenomas or carcinomas and matched controls, further support for the concept that bile acids have a role to play in the development of large bowel tumours is shown.

References


Relationship between duodenal bile acids and colorectal neoplasia

Relationship between duodenal bile acids and colorectal neoplasia.

R J Moorehead, G R Campbell, J D Donaldson and S T McKelvey

_Gut_ 1987 28: 1454-1459
doi: 10.1136/gut.28.11.1454

Updated information and services can be found at:
http://gut.bmj.com/content/28/11/1454

**Email alerting service**

_These include:_

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections
Colonic cancer (1547)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/